CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators with a proprietary High Affinity ...
Ventus Therapeutics Inc. closed a $140 million series C financing to continue scaling its platform to address previously undruggable targets. The company said it plans to advance programs targeting ...
Please provide your email address to receive an email when new articles are posted on . Aviceda Therapeutics secured $207.5 million in Series C financing to advance the AVD-104 program in geographic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback